Global Dolutegravir Market Size was valued at USD 9.44 Billion by 2035 | CAGR of 5.1%
Category: HealthcareGlobal Dolutegravir Market Size was valued at USD 9.44 Billion by 2035
According to a Research Report Published by Spherical Insights & Consulting, The Global Dolutegravir Market Size is expected to Grow from USD 5.46 Billion in 2024 to USD 9.44 Billion by 2035, at a CAGR of 5.1% during the forecast period 2025-2035.
Get more details on this report -
Browse 210 Market Data Tables And 45 Figures Spread Through 190 Pages and In-Depth TOC On the "Global Dolutegravir Market Size, Share, and COVID-19 Impact Analysis, By Type (10mg Tablets and 50mg Tablets), By Application (Prevent HIV Infection Following Potential Exposure, Treatment of HIV Infection, and Pediatric Use), By End-user (Hospitals, Clinics, Home care, and Others), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2025 – 2035." Get Detailed Report Description Here: https://www.sphericalinsights.com/reports/dolutegravir-market
Dolutegravir (DTG) is a second-generation HIV-1 integrase inhibitor used with other antiretroviral drugs to treat HIV/AIDS and as part of pre-exposure prophylaxis (PrEP), effectively blocking viral replication. The market is driven by WHO recommendations for DTG-based regimens, such as TLD, which offer high resistance protection, safety, and improved adherence through fixed-dose single-tablet combinations. Growth is further supported by the rollout of pediatric formulations, adoption in low- and middle-income countries through international funding, and two-drug regimens that reduce pill burden. Large-scale procurement programs, voluntary licensing agreements, and access to affordable generics, particularly in Africa, continue to accelerate global market expansion for dolutegravir. The dolutegravir market faces challenges from resistance, side effects, weight gain, and emerging antiviral competition.
The 50mg tablets segment dominated the market in 2024 and is projected to grow at a substantial CAGR during the forecast period.
Based on the type, the dolutegravir market is divided into 10mg tablets and 50mg tablets. Among these, the 50mg tablets segment dominated the market in 2024 and is projected to grow at a substantial CAGR during the forecast period. The 50 mg dolutegravir’s high HIV suppression efficacy and once-daily dosing make it a preferred treatment, enhancing patient adherence and driving growth in this segment of the market.
The treatment of HIV infection segment accounted for the largest share in 2024 and is anticipated to grow at a remarkable CAGR during the forecast period.
Based on the application, the dolutegravir market is divided into prevent HIV infection following potential exposure, treatment of HIV infection, and pediatric use. Among these, the treatment of HIV infection segment accounted for the largest share in 2024 and is anticipated to grow at a significant CAGR during the forecast period. The high global HIV/AIDS prevalence drives demand for effective antiretrovirals like dolutegravir, whose potent HIV inhibition, once-daily dosing, and growing awareness of treatment options make it a preferred therapy.
The hospitals segment accounted for the highest market revenue in 2024 and is anticipated to grow at a significant CAGR during the forecast period.
Based on the end-user, the dolutegravir market is divided into hospitals, clinics, home care, and others. Among these, the hospitals segment accounted for the highest market revenue in 2024 and is anticipated to grow at a significant CAGR during the forecast period. High patient volumes and advanced facilities make hospitals crucial for dolutegravir administration, providing trained staff and infrastructure to ensure safe, effective treatment, driving significant growth in this segment.
North America is expected to hold the majority share of the global dolutegravir market during the forecast period.
Get more details on this report -
North America is expected to hold the majority share of the global dolutegravir market during the forecast period. The high HIV/AIDS prevalence drives demand for antiretrovirals like dolutegravir. Segment growth is supported by strong healthcare infrastructure, availability from key market players, and increased public awareness of HIV/AIDS and treatment options, collectively boosting accessibility and demand for the drug.
Asia Pacific is anticipated to grow at the fastest pace in the global dolutegravir market during the forecast period. Rising HIV/AIDS prevalence and awareness, along with improving healthcare infrastructure and expenditure, boost dolutegravir demand. Availability of lower-cost generics from regional manufacturers further enhances affordability, accessibility, and widespread use, driving market growth in the region.
Major vendors in the global dolutegravir market are Aurobindo Pharma, ViiV Healthcare, Mylan N.V., Adcock Ingram Limited, Sun Pharmaceutical Industries, Aurobindo Pharma, Cipla Ltd., Laurus Labs, Emcure Pharmaceuticals, Hetero Labs Limited, Desano Inc., Zydus Lifesciences Limited, and Others.
Key Target Audience
- Market Players
- Investors
- End-users
- Government Authorities
- Consulting and Research Firm
- Venture capitalists
- Value-Added Resellers (VARs)
Key Market Development
- In February 2024, ViiV Healthcare announced that Dovato (dolutegravir/lamivudine) is now available in a U.S. blister pack. Approved for adults with HIV-1, it can be used as a complete first-line regimen or to replace stable ARV therapy in virologically suppressed patients without prior treatment failure or resistance.
- In May 2023, Laurus Labs received in-principle USFDA approval to launch the world’s first Dolutegravir Oral Dispersible Film (ODF) for treating HIV/AIDS in children and infants. This child-friendly formulation complements existing pill and liquid options, supporting antiretroviral therapy and improving management of HIV/AIDS symptoms in young patients.
Market Segment
This study forecasts revenue at global, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the dolutegravir market based on the below-mentioned segments:
Global Dolutegravir Market, By Type
- 10mg Tablets
- 50mg Tablets
Global Dolutegravir Market, By Application
- Prevent HIV Infection Following Potential Exposure
- Treatment of HIV Infection
- Pediatric Use
Global Dolutegravir Market, By End-user
- Hospitals
- Clinics
- Home care
- Others
Global Dolutegravir Market, By Regional Analysis
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Rest of Asia Pacific
- South America
- Brazil
- Argentina
- Rest of South America
- Middle East & Africa
- UAE
- Saudi Arabia
- Qatar
- South Africa
- Rest of the Middle East & Africa
About the Spherical Insights & Consulting
Spherical Insights & Consulting is a market research and consulting firm which provides actionable market research study, quantitative forecasting and trends analysis provides forward-looking insight especially designed for decision makers and aids ROI.
Which is catering to different industry such as financial sectors, industrial sectors, government organizations, universities, non-profits and corporations. The company's mission is to work with businesses to achieve business objectives and maintain strategic improvements.
CONTACT US:
For More Information on Your Target Market, Please Contact Us Below:
Phone: +1 303 800 4326 (the U.S.)
Phone: +91 90289 24100 (APAC)
Email: inquiry@sphericalinsights.com, sales@sphericalinsights.com
Contact Us: https://www.sphericalinsights.com/contact-us
Need help to buy this report?